沙格列汀治疗2型糖尿病合并代谢综合征患者的临床效果及对其微炎症状态的影响

Clinical effect of Saxagliptin in the treatment of patients with type 2 diabetes mellitus complicated with metabolic syndrome and its influence on microinflammatory state

目的探讨沙格列汀治疗2型糖尿病合并代谢综合征患者的临床效果及对其微炎症状态的影响。方法选取2017年1月~2018年8月我院收治的102例2型糖尿病合并代谢综合征患者作为研究对象,采用随机数字表法将其分为常规组(n=51)和实验组(n=51)。常规组患者予以二甲双胍治疗,实验组患者在常规组的基础上联用沙格列汀治疗。比较两组患者的临床疗效、治疗前后糖脂代谢指标[空腹血糖(FPG)、空腹胰岛素(FPI)、胰岛素抵抗指数(HOMA-IR)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、总胆固醇(TC)]、炎症因子[肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)]含量及不良反应总发生率。结果实验组患者的治疗总有效率(94.12%)高于常规组(74.51%),差异有统计学意义(P<0.05)。两组患者治疗后的FPG、FPI、HOMA-IR、HbA1c、TG、TC、TNF-α、IL-6、hs-CRP均低于治疗前,差异有统计学意义(P<0.05);实验组患者治疗后的FPG、FPI、HOMA-IR、HbA1c、TG、TC、TNF-α、IL-6、hs-CRP均低于常规组,差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论应用沙格列汀联合二甲双胍治疗2型糖尿病合并代谢综合征的效果明显,可降低糖脂水平及炎症因子,且应用安全,值得推广。

Objective To investigate the clinical effect of Saxagliptin in the treatment of patients with type 2 diabetes mellitus complicated with metabolic syndrome and its influence on microinflammatory state.Methods A total of 102 patients with type 2 diabetes complicated with metabolic syndrome admitted to our hospital from January 2017 to August 2018 were selected as research objects,and they were divide into conventional group(n=51)and experimental group(n=51)according to the random number table method.The conventional group was treated with Metformin,and the experimental group was treated with Saxagliptin on the basis of conventional group.The clinical efficacy,glycolipid metabolic indicators(fasting plasma glucose[FPG],fasting insulin[FPI],insulin resistance index[HOMA-IR],glycated hemoglobin[HbA1c],triacylglycerol[TG],total cholesterol[TC]),inflammatory factor(tumor necrosis factor-α[TNF-α],interleukin-6[IL-6],high-sensitivity C-reactive protein[hs-CRP])contents before and after treatment,and total incidence rate of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the experimental group(94.12%)was higher than that in the conventional group(74.51%),and the difference was statistically significant(P<0.05).After treatment,FPG,FPI,HOMA-IR,HbA1c,TG,TC,TNF-α,IL-6,and hs-CRP in the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05).The FPG,FPI,HOMA-IR,HbA1c,TG,TC,TNF-α,IL-6,and hs-CRP in the experimental group after treatment were lower than those in the conventional group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence rate of adverse reactions between the two groups of patients(P>0.05).Conclusion The effect of Saxagliptin combined with Metformin in the treatment of type 2 diabetes mellitus complicated with metabolic syndrome is obvious,it can reduce the levels of glycolipid and inflammatory factors with application security,which is worth promoting.